![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/0bb93511db3aef416059037b1bad05516c60944e-5824x3264.jpg?fit=crop&auto=format)
FDA Approves Sparsentan, With Data Indicating Slowing of Kidney Function Decline in IgA Nephropathy
The FDA has announced full approval for sparsentan (Filspari; Travere Therapeutics), an oral, once-daily, non-immunosuppressive medication which can significantly slow the decline of kidney function in adult patients with primary immunoglobulin A …